Codexis delivered strong revenues of $15.3 million in Q2 2025, a significant increase from the previous year, primarily due to variability in customer manufacturing schedules and clinical trial progression. The company also strengthened its cash position by raising $27.3 million to support the expansion of its ECO Synthesis platform, which saw increased external validation and ongoing engagements.

Codexis posted $7.5 million in revenue for Q1 2025, a sharp decline from the prior year due to absence of one-time licensing income. The company reported a net loss of $20.7 million, citing higher R&D expenses and a delay in a $2.5 million customer order. Despite the setback, Codexis emphasized strategic progress with its ECO Synthesis™ platform and maintained its 2025 revenue guidance.

Codexis reported a 17% increase in total revenues for Q4 2024 to $21.5 million, excluding PAXLOVID™ enzyme sales, compared to $18.4 million in Q4 2023. The company's net loss for Q4 2024 was $10.4 million, or $0.13 per share. For the full fiscal year 2024, total revenues were $59.3 million, a 4% decrease from $62.0 million in FY 2023, excluding PAXLOVID™ enzyme sales.

Codexis reported a strong third quarter, exceeding product revenue targets and extending its cash runway into 2027 with a $31 million raise. The company also out-licensed its genomics enzymes portfolio to Alphazyme, reinforcing its focus on pharmaceutical manufacturing and the ECO Synthesis™ platform.

Codexis reported total revenues of $8.0 million for Q2 2024, compared to $21.3 million in Q2 2023. The company reiterated its full-year 2024 financial guidance. They had $73.2 million in cash, cash equivalents and short-term investments as of June 30, 2024.

Codexis reported a 32% increase in total revenue to $17.1 million for Q1 2024, driven by a 14% increase in product revenue and a significant order for its double-stranded RNA (dsRNA) ligase. The company is finalizing the enzymatic synthesis of a full-length oligonucleotide and expects to complete this by TIDES USA. Codexis reiterated its 2024 financial guidance and expects to fund its planned operations through positive cash flow, expected around the end of 2026.

Codexis reported a 42% increase in total revenues, excluding enzyme sales related to PAXLOVID™, reaching $18.4 million for Q4 2023. The company's net loss decreased to $7.2 million, or $0.10 per share, compared to a net loss of $12.6 million, or $0.19 per share, for Q4 2022.

Codexis reported a decrease in total revenue to $9.3 million for Q3 2023, compared to $34.5 million in Q3 2022. The company is focusing on its ECO Synthesis™ platform and Pharmaceutical Manufacturing business, with expectations to fund operations to positive cash flow around the end of 2026.

Codexis' total revenues, excluding enzyme sales related to PAXLOVID™, increased by 46% to $21.3 million for Q2 2023 compared to $14.6 million in Q2 2022. The company is prioritizing the advancement and commercialization of its ECO Synthesis™ technology platform and its highly complementary Pharmaceutical Manufacturing business. They streamlined operations, including a 25% headcount reduction, extending the projected cash runway to mid-2026.

Codexis' total revenues for Q1 2023 were $13.0 million, an 8% decrease compared to Q1 2022 excluding enzyme sales related to PAXLOVID™. The net loss for the quarter was $22.6 million, or $0.34 per share.

Codexis reported a 24% increase in total revenue for Q4 2022, driven by enzyme sales related to PAXLOVIDTM. However, excluding these sales, total revenues decreased slightly. The company is prioritizing programs in life sciences, biotherapeutics, and pharmaceutical manufacturing.

Codexis reported a decrease in total revenue by 6% to $34.5 million for Q3 2022, primarily due to lower enzyme sales related to PAXLOVID™. The company is refining its strategy to focus on areas with a competitive advantage to drive long-term success.

Codexis reported a strong second quarter with a 51% increase in total revenue and a 135% increase in product revenue compared to the same period last year. The company is making progress across its growth drivers and is particularly pleased with the strength of its product revenue, driven by sales of CDX-616 for Pfizer's PAXLOVID™ and strong sales to other key pharma manufacturing customers.

Codexis reported a strong first quarter in 2022, with total revenues up 96% year-over-year and product revenues up 200%. The company is reiterating its full-year revenue guidance of $152 million to $158 million.

Codexis announced financial results for Q4 and fiscal year ended December 31, 2021. The company's total revenues for the fourth quarter 2021 were $24.5 million, an increase of 16% from $21.0 million in the fourth quarter 2020.

Codexis reported a strong third quarter, with a 100% increase in total revenues to $36.8 million, driven by significant growth in the Sustainable Manufacturing business, particularly sales of enzymes for Pfizer's COVID-19 antiviral therapeutic candidate. The company also saw record product gross margin and established new agreements to extend its sitagliptin product business.

Codexis reported a 70% increase in total revenue, driven by a 227% increase in product revenue. The company's product gross margin climbed to 71%. Due to the strong performance, Codexis raised its full-year revenue guidance.

Codexis reported a 23% increase in total revenue to $18.0 million, driven by a 101% increase in product revenue. The company's product gross margin climbed to 59%. Net loss for the quarter was $9.1 million, or $0.14 per share.

Codexis delivered strong results in Q4 2020, with total revenues increasing by 12.8% compared to Q4 2019. Product revenues saw a significant increase due to higher sales of branded pharmaceutical products, while R&D revenues decreased due to lower revenue from Novartis. The company's product gross margin also improved, driven by increased sales of higher margin products.

Codexis reported total revenues of $18.4 million for the third quarter of 2020. Product revenue exceeded expectations, with Merck, Allergan, and Urovant Sciences as leading contributors. The company expects full year product revenue to be above pre-COVID-19 guidance and close to 2019 levels.

Codexis reported better-than-expected revenues of $15.0 million for Q2 2020, a 21% increase year-over-year, driven by strong growth in R&D revenues, which grew 72%. The partnership with Takeda contributed significantly to the quarter's revenues.

Codexis reported $14.7 million in total revenues for Q1 2020, driven by a 26% year-over-year increase in R&D revenue. The company withdrew its 2020 financial guidance due to the uncertainty of the potential impact of the COVID-19 pandemic.

Codexis reported strong fourth-quarter revenues of $18.7 million, a 16% increase over the prior-year quarter. The Performance Enzymes segment led the way in 2019 with a 24% increase in revenues. The company's outlook for 2020 is for another year of double-digit revenue growth, up 14% to 20% over 2019.